Scorpion venom helps treat brain tumors


A new method of delivering a dose of radioactive iodine by using a manufactured version of scorpion venom as a carrier targets gliomas without affecting neighboring tissue or body organs.

The first trial in human patients showed the approach to be safe. A larger phase II trial is under way to assess the effectiveness of multiple doses. Dr. Adam N. Mamelak, a neurosurgeon at Cedars-Sinai Medical Center in Los Angeles, led the phase I trial and is first author of an article in the August Journal of Clinical Oncology.

The key ingredient is TM-601, a synthetic version of a peptide found in the venom of the giant yellow Israeli scorpion (Leiurus quinquestriatus). TM-601 can break through the blood-brain barrier, binding to glioma cells and impeding their growth. If further studies confirm TM-601's properties, it could be used in tandem with standard treatments and allow for reduced doses, the researchers said.

Related Videos
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2023 MJH Life Sciences

All rights reserved.